Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase 3 Study to Evaluate the Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases.

NCT03988426 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT03988426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03988426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase 3 Study to Evaluate the Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases.
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
March 7, 2017
Completion date
January 26, 2018
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency disorder